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ABSTRACT 
 
Alshamrany, Abdullah. M.S. Department of Physics, Wright State University, 2018. 
Determination of Dose Effects when Including Attenuation of the Treatment Table into 
Treatment Planning Computer Modeling. 
 
 
 
During radiation treatment, the patient commonly lies on a horizontal treatment table 
called a couch. The material used for the couch is chosen during the manufacturing 
process so as to minimize the effect of the couch on dose delivery, but it still has an 
effect.  In addition to couch attenuation on the beam, the modern approach of using 
multiple beam angles for dose delivery makes treatment planning in the presence of the 
couch more challenging. However, the effect of the couch is not always considered when 
creating treatment plans, generally due to treatment planning software limitations.  In this 
evaluation, the effects of the Varian Medical Systems, Inc® (Palo Alto, CA) Model 
IGRT Couch Top® on the dose distribution of head and neck cancer treatment was 
determined for a linear accelerator operating at 6 MV. Four head and neck cancer patients 
were selected for the study. Varian Model Eclipse® treatment planning software was 
used to create two Volumetric Modulated Arc Therapy (VMAT) plans.  One plan 
assumed the couch was not present, and one assumed it was present. Both plans were 
optimized to achieve the same physician directed dose objectives.  Comparisons were 
then made using the planning system’s Dose Volume Histogram (DVH) statistical and 
volumetric data. Dose changes to the tumor volumes along with normal tissue structures 
around the target area were clinically assessed. The mean dose to the tumor 
iv 
was reduced by 0.5 to 0.65 Gy as a consequence of including the couch during planning. 
Doses to surrounding normal tissues showed variable, yet significant effects. 
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1. INTRODUCTION  
          In current external beam radiotherapy such as intensity modulated radiotherapy 
(IMRT) and volumetric modulated arc therapy (VMAT), patients should receive the 
prescribed dose with higher accuracy than for ordinary three-dimensional conformal 
radiation therapy (3DCRT). In all of these treatment techniques, the treatment fields are 
routinely required to penetrate the treatment couch. In the past, medical physicists have 
not considered the couch during the computerized treatment planning process due to 
complexities in modeling the device with high accuracy. This remains common practice 
for most institutions even if the table is made of low-density carbon fiber.1,2 Studies have 
shown that a variety of currently marketed couch tops produce significant beam 
attenuation. McCormack has found that a 6 MV photon beam is attenuated by 2% at 0° 
angle and a remarkable 9% at 70° angle respect to posterior beam normal incidence.3 
Njeh has measured the attenuation of the carbon fiber couch for the case of intensity-
modulated radiation therapy fields and has found a couch attenuation as high as 10% at  6 
MV.4 Moreover, Seppälä has studied the impact of eight couchtops on 6 MV photon 
beam, and found that the maximum attenuation of 10.8% at an angle of 110°.5 The 
Varian® Exact couch effect on 6 MV photon beam has been studied by Veira, et al and 
showed attenuation of up to 15% for oblique beams passing through the couch.6
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The Varian® IGRT Couch Top® has also been investigated for attenuation by Munjal et 
al and showed a maximum attenuation of 4.8%.7  
          Even though treatment couches are identified to cause beam attenuation, studies 
about the effect of considering the couch during creation of the treatment plan are 
insufficient, especially with regards to how attenuation due to the couch plays a role in 
altering dose-volume histogram (DVH) data.8 Practical methods are needed to model the 
couchtops on the patient’s treatment plan. In an attempt to advance the science, studies by 
Myint, Zhihui, and Gerig have evaluated a method for adding treatment couch structures 
into treatment planning system (TPS) by copying computed tomography (CT) images of 
couches and then inserting this structure into their TPS.9,10,11 Mihaylov added an 
ExacTrac® couch into the Pinnacle® treatment planning system by manually contouring 
the location and shape of the couch on CT scan data, then assigning Hounsfield units to it 
that relate to physical density.12 All the studies found that the agreement between the 
measured and predicated attenuation in phantom is within 1.4-2% with phantom 
measurements. However, none of these studies involved actual patient cases for 
investigating the impact of treatment couches on dose distributions. 
      A study, evaluating the impact of a Varian® IGRT Couch Top® in the management 
of prostate treatments via Varian RapidArc® was published by Vanetti, showing the 
mean dose differences to the target and normal structures between plans with and without 
Varian® IGRT Couch Top®. For a 6 MV photon beam energy, the mean dose to the 
prostate gland dropped by 1.3 Gy over the entire course of treatment.13 This study is not 
directly applicable to the current study for three reasons.  First, the prostate is localized, 
while head and neck tumors are distributed in a non-uniform fashion through the body.
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Second, the couch is thicker in the region needed for prostate treatment than for head and 
neck treatment.  Finally, the surrounding healthy organs are in different locations and 
have different dose constraints than for head and neck tumors.  In this study, the effect of 
including the couch during treatment planning on doses to tumor targets and surrounding 
tissues will be investigated, focusing on head and neck tumors. The treatment plans all 
use the VMAT technique and the Varian TrueBeam® particle accelerator, and the couch 
under consideration is the Varian® IGRT couch exclusively. 
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2.0 Background and Theory 
2.1 External Beam Radiation Therapy 
          A linear accelerator is a device used to perform external beam radiation therapy by 
producing a focused beam of x-ray that can be aimed to patients. Radiation generation all 
starts with a heated cathode tube, where electrons are boiled off. Those electrons are 
pulled into a linear tube using an array of quadrupoles that constitute a magnetic field. 
Along with those magnets, an RF waveguide additionally directs a high frequency wave 
for further acceleration. Energy increases of upwards to 150 keV/cm are possible using 
these means. A series of alpha magnets in the gantry bend the electron beam upward and 
then down, where the patient is to be treated. It is here that the beam can be directed out 
for direct electron irradiation, or alternatively collide with a target to yield 
bremsstrahlung x-rays when photon radiation is needed.14 This x-ray is first collimated by 
a fixed primary collimator, found immediately below the x-ray target.14 A flattening filter 
made of lead or tungsten is used to make the round profile of the x-ray beam more 
uniform before it passes through a secondary set of collimators.14 The secondary 
collimators consist of two movable pairs of lead or tungsten jaws which allow forming a 
rectangular opening field.14  
          Linear accelerators have a gantry that allows the source to rotate 360° about a 
horizontal axis. The point of intersection of the gantry axis rotation and the collimator 
axis (central axis of the beam) is defined as the isocenter (Figure 1).15 
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Figure 1: Schematic of a linear accelerator.  
(Source: E. B. Podgorsak and J. H. Hendry, Radiation Oncology Physics: A Handbook 
for Teachers and Students (International Atomic Energy Association, Vienna, 2005) 
 
       This rotation allows the treatment beam to enter patients at a defined angle of 
incidence. While the gantry can move rotationally, the radius of rotation cannot be 
changed. The distance between the beam source and patients can be controlled by six 
degree of freedom movement of the treatment couch along pitch, roll, raw, longitudinal, 
lateral, and vertical axes.15 
2.2 Interaction of Photons with Matter 
         When traversing matter, photons will penetrate without interaction, scatter, or be 
absorbed. The photon interactions are primarily photoelectric effect, Compton scattering, 
and pair production.16 
         Photoelectric effects take place when low energy photons interact with high atomic 
number materials.16 In this phenomenon the photon interacts with an atom and removes
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one of the orbital electrons. The photoelectric process predominates when both the 
energy of incident photon and the electron binding energy are in the same range.14 The 
kinetic energy of the ejected photoelectron is equal to the difference between the incident 
photon energy and electron binding energy.14,16 Compton scattering occurs when high 
energy incident photon interacts with outer shell elections. In this process, the electron 
receives some energy from the incident photon. The ejected electron and the recoiling 
photon are emitted with some reduction in energy relative to the incident photon. Pair 
production can only occur when the energy of the incident photon exceeds 1.02 MeV.16 
In this process, the photon energy is converted due to the electromagnetic field of the 
atom nucleus and producing a pair consisting of electron and positron. The probability of 
this interaction increases rapidly with atomic number.14 
          The interaction mechanisms in varying degree cause the photon beam 
attenuation.16 The beam attenuation is defined as the reduction of the photon number as it 
passes through matter. Mathematically,  
I (x) = Io e
-μ x 
where I (x) is the intensity transmitted by a thickness x of the material, Io is the incident 
photon intensity, and μ is the attenuation coefficient.14 For a narrow monoenergetic 
photon beam the relationship between the transmitted intensity and the absorber thickness 
is exponential. However, an actual beam used in radiation therapy consists of a spectrum 
of photon energies. Therefore, the attenuation is not well defined for any specific energy, 
albeit does follow exponential interaction probabilities. As the absorber thickness 
increases, the average energy of the transmitted polyenergetic photon beam increases (the 
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beam becomes harder). Since lower energy photons have a larger coefficient of 
attenuation than higher energy photons, lower energy photons attenuate quicker. 
          These x-ray processes are not directly ionizing. All of the primary photon 
interactions with matter produce fast moving charged particles, electrons, in the medium. 
These electrons interact with and transfer energy to surrounding particles.14 For 
megavoltage radiotherapy, the energy of the incident photons reaching the patient’s 
surface is of the order of 4-25 MV.14 These high energy photons interact with relatively 
low effective atomic number of tissue by Compton scattering.17After the interaction, the 
photon is scattered at a relatively small angle yet still moves in a more forward direction. 
Abiding by the laws of conservation of energy and momentum, the ejected electron also 
moves in a more forward direction. Remaining energy subtended in the interaction is 
absorbed by the medium causing the scattering event.18  
2.3 Absorbed Dose 
          It is a value quantifies the amount of electron released energies that absorbed by a 
unit mass of matter. The old unit for absorbed dose is the rad (radiation absorbed dose) 
which represents 100 ergs imparted to gram of matter.14 
1 rad = 100 ergs/g = 10-2 J/kg 
        The SI unit for the absorbed dose is the gray which represents the absorption of 1 
joule of energy per kilogram of matter.  
1 Gy = 1 J/kg 
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2.4 Dose Distribution 
           As a photon beam travels through a medium, it causes the release of electrons. By 
contrast, an electron beam can simply be absorbed, causing an absorbed dose. An x-ray 
beam must first ionize the medium, causing those electrons to be absorbed, causing an 
absorbed dose. 
           For megavoltage beams, the maximum dose, Dmax, is located at a depth called 
maximum depth, dmax, beyond the patients’ surface. The distance between the patient’s 
surface and the dmax is known as the dose build up region.
14 As the high energy photon 
beam enters the surface, high speed electrons are released.14 These high-speed electrons 
deposit their energy to a distance away from the surface, where the ejected electron 
reaches its range. The range is the distance traveled before interacting so many times that 
it has very little energy left, therefore becoming completely absorbed.14 Since the dose is 
delivered by the electrons, the dose increases with depth until it reaches a maximum. 
Also, as the production of the electrons depends on the intensity and the energy of the 
incident photon beam, the number of electrons produced decreases as the photon beam 
intensity and energy decrease further in the medium.14 This reduction in the photon beam 
energy correlates with the kinetic energy released in the medium (kerma) Figure 2.14
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Figure 2: Schematic plot of absorbed dose and kerma as functions of depth. (Source: The 
Physics of Radiation Therapy (p. 164), by F. M. Khan, 2003, Philadelphia, PA: Wolters 
Company. Copyright 2003by Lippincott Williams and Wilkins.) 
           The central axis dose distribution through a medium can be characterized using a 
Percent Depth Dose (PDD) curve. The PDD is defined as the ratio of the absorbed dose at 
any depth (d) to the maximum absorbed dose at dmax. As the photon beam energy 
increases, the dmax in the phantom or other materials increases, and thus the PDD 
increases comparatively for depths beyond dmax Figure 3.
14 
 
Figure 3: Central axis depth dose distribution for different quality photon beam. 
(Source: The Physics of Radiation Therapy (p. 163), by F. M. Khan, 2003, Philadelphia, 
PA: Wolters Company. Copyright 2003by Lippincott Williams and Wilkins.)
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2.5 Hounsfield Unit 
          In Computed Tomography (CT), the linear attenuation coefficients (μ) of different 
anatomical structures are measured and computed to form CT images.19 Since μ is highly 
energy dependent and the CT x-ray beam is polyenergetic, this makes the direct 
interpretation of the computed attenuation coefficient values difficult.19 Therefore, the 
computed attenuation coefficient is represented as a Hounsfield unit (HU). The HU is a 
measure of the attenuating properties relative to water. HU is defined for different tissues: 
HU = (
μ tissue – μ water
μ water
) . 1000 , 
  where μ tissue is the attenuation coefficient of tissues and μ water is the attenuation 
coefficient of water. The HU for water is 0 HU. The HU value for air can be 
approximated as having no attenuation, resulting in a value of -1000 HU.19 Although the 
HU still retains some dependence on photon energy, since μwater and μtissue don’t 
necessarily change with photon energy in the same proportion, the primary advantage of 
HU is that it is much less sensitive to photon energy due to being scaled to water. 
2.6 Target Volumes 
           The International Commission on Radiation Units and Measurements (ICRU) in 
Reports no. 50 and 62 recommended that three target volumes be identified in a treatment 
plan. Those three target volumes are: Gross Tumor Volume (GTV), Clinical Target 
Volume (CTV), and Planning Target Volume (PTV).20 
           GTV represents the palpable tumor which is visible in the medical images. CTV 
surrounds the GTV and includes affected tissue adjacent to the main tumor mass. Lastly, 
PTV includes both GTV and CTV with additional internal margin that account for the 
variation of tumor size during therapy, and the movement of the patient.20
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2.7 Current Treatment Modalities 
           In the past, external beam radiation from a Linac involved a fixed shape aperture 
where the radiation exited. Advances in technology then lead to the ability to further 
shape the aperture based on the shape of target at depth. One development was to insert a 
block. The block is a composite metal made of a Lipowitz's alloy substance containing 
Bismuth, Lead, Tin, and Cadmium. It melts at around 160° F, permitting its solid form to 
take shape when it cools. The physical demands of interchanging these blocks lead to the 
innovation of a multi-leaf collimator (MLC). The MLC is a set of retractable leafs, each 
made of Tungsten, and 7 cm thick. With an electronic motor, the leafs can individually be 
driven to shape the aperture as needed. Current technology involves the active motion of 
these leaves during treatment for static beams at a fixed angle, such as for Intensity 
Modulated Radiation Therapy (IMRT). However, they can also be used with treatments 
involving beams that rotate around the patient, such as with Volumetric Modulated Arc 
Therapy (VMAT). Both of these treatment modalities use modern computer-controlled 
intensity modulated systems that make use of the multileaf collimator Figure 4. 
 
Figure 4: Dynamic multileaf collimators
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          In IMRT treatments multiple fields can be applied through a step and shoot 
method. The entire plan is divided into different beams, each with a set of shapes that the 
MLC must form during treatment. As the machine transitions from one gantry angle to 
another, the radiation beam is turned off .14 The VMAT treatment method is similar to 
IMRT in that that each beam has a set of shapes that the MLC must form during 
treatment. However, there is no lag in transition as there is no defined angle that the beam 
must stop. The machine is constantly rotating around the patient. The only caveat is that 
the shape formed by the MLC must be precise at the desired angle during rotation. The 
machine is constantly moving and so is the MLC. 14Like IMRT, VMAT can reduce the 
treatment time, yet VMAT is more efficient. One VMAT beam can do the same thing 
that 179 IMRT beams can do, or comparatively with 179 conformal beams that use metal 
alloy blocks that need interchanged. 
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3.0. METHODS AND MATERIALS 
3.1 Planning 
          The treatment delivery considered in this research was given using a Varian® 
Model TrueBeam® linear accelerator (LINAC) operating at 6 MV. It possessed a Varian® 
Model NDS120® 120 multi-leaf collimator. This research addresses the modern delivery 
technique of Volumetric Modality Arc Therapy (VMAT). More specifically, this method 
of delivery is known as Varian® RapidArc®, as it is intended for use with a Varian 
LINAC.  
          The goal of this study was to evaluate the impact of the treatment couch on the 
dose distribution.  Therefore, it is important to identify the dosimetric consequences of 
modeling the couch in the planning process, since treatment of the patient involves some 
of the beam potentially passing through the plastic couch that they lay on. To achieve this 
goal, four treatment plans were selected that each ignored the treatment couch during the 
planning process. For simplicity in labeling here, I have chosen to refer to these plans as 
“Excluded couch plans”. The Varian® Model Eclipse® treatment planning system was 
used for the calculation of absorbed dose distributions in those plans without including 
attenuation from the treatment couch. In this study, those plans were copied to insure 
identical geometry and then the treatment couch was inserted. After the couch was 
inserted, the Eclipse® treatment planning system was made to re-optimize gantry and leaf 
motion files and then re-calculate the dose distribution again. I refer to those new plans 
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as” Couch included plans”. Therefore, each patient had two plans; a Couch excluded plan 
and a Couch included plan. The only difference between these two plans are the absence 
or the presence of the couch. Differences in the dose distribution and or statistics 
referenced from dose-volume histogram (DVH) analysis are investigated to determine the 
consequences of couch incorporation. 
3.2 Procedure 
3.2.1 Patient selection and the cases descriptions 
          Four head and neck cancer patients were randomly selected. Two patients had 
squamous cell carcinoma at the base of the tongue, with a disease classification Stage II 
(T2, N0, M0) for both cases. The third patient has the squamous cell carcinoma of the 
lower neck, with disease classification Stage III (T3, N0, M0). The last patient has the 
squamous cell carcinoma of the left tonsil with disease classification IV (T3, N2, M0). 
Therefore, all of the patients have a bit different disease progression. Still, there is 
something that can be said about the general consequences of target and normal organ 
coverage when planned nearly identically. 
3.2.2 Treatment Plan Set up  
          Patient’s CT images are imported to the eclipse treatment planning system. Then, 
both target structures and organs at risk (OARs) around the tumor were identified on the 
CT images. After that, the dose constraints are input on the TPS. In the case of the couch 
included plan, the IGRT is inserted. The final step is the optimization process where the 
TPS works out the gantry angles, rotation rates and MLC settings to achieve the dose 
constraints or in other word the TPS objectives. 
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3.2.2.1 Contouring both Target Structures and OARs         
         Using a computerized treatment planning system, and making use of the patient’s 
CT scan data, the board certified medical physicist or their dosimetrist assistant uses 
outlining tools to contour all normal structures. Since these structures are at risk for 
radiation exposure and possibly some toxicity (functional affects), each are referred to as 
an organ at risk (OAR). The radiation oncologist is responsible for contouring of tumor 
volumes or other principal target structures, such as a nerve. For all patients, the clinical 
target volume (CTV 70) with 5-mm margin was created around the gross tumor volume 
(GTV). The planning target volume (PTV 70) for CTV 70 was created with 3-mm margin 
from the CTV 70 to account for the set-up uncertainties and daily repositioning errors. 
Margins were chosen by the radiation oncologist to account for physiological factors such 
as patient breathing. The secondary target was the CTV of lymph node chain with high 
risk, named as CTV 63. PTV 63 with 3-mm margin was created from the CTV 63. The 
third target was CTV 56, accounting for the lymph node with lower risk. The 3-mm 
margin that was given to CTV 56 to create PTV 56. The critical structures included the 
spinal cord, and parotid glands, and other adjacent organs local to the target PTV 
structures (Figures 5 and 6).  
         All plans were generated for a treatment in 35 fractions, to deliver total dose of 70 
Gy, 63 Gy, and 56 Gy to PTV 70, PTV 63, and PTV 56 respectively. These plans did not 
include the couch top when the Eclipse® treatment planning system calculated the dose 
distribution.
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Figure 5: CT image of the tongue base with target structures (red area is PTV 70, orange 
area is PTV 63, and blue area is PTV 56) 
 
 
Figure 6: CT image of the tongue base case with normal organs (green area is R. Parotid, 
blue area is oral cavity, sky blue area is spinal cord, and yellow area is larynx, and light 
green area is L. Parotid)
 
17 
3.2.2.2 Dose Constraints for Target Structures and OARs 
         The dose constraints for the target structures and organs at risk are summarized in 
table 1, and 2.  
Target structures 
 
Parameter 
 
Dose % limit 
[% of 70 Gy] 
 
PTV 70 
 
D99 
 
97 
 
D95 
 
99 
PTV 63 
 
D99 
 
87 
D95 
 
89 
PTV 56 
 
D99 
 
77 
D95 
 
79 
Table 1: Target structures dose constraints 
 
Organs at risk 
 
Parameter 
 
Dose % limit 
[% of 70 Gy] 
 
Spinal cord 
 
Max dose 
 
< 64 
Brain stem 
 
Max dose 
 
< 64 
Mandible 
 
D30 
 
< 93 
L. Parotid 
 
Mean 
 
< 35 
R. Parotid 
 
Mean 
 
< 35 
Larynx 
 
Mean 
 
< 79 
Table 2: OARs dose constraints
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3.2.2.3 Inserting the IGRT Couch on the Couch Excluded Plans 
          The couch considered in this study is the Varian® IGRT Couch Top®. It is made of 
a carbon fiber superficial shell and a radio-transparent foam filling the internal cavity. 
This couch is manufactured with three thicknesses (thin, middle, thick) increasing from 
the section of the couch used for head treatments (right side as illustrated in Figure 7) 
towards the section used for abdomen treatments. Even though the lower portion of the 
couch resembles that of an inclined plane with a shallow angle, the couch is uniquely 
designed with a six-degrees-of-freedom (6DOF) stepper system, enabling a flat upper 
surface for patient positioning, no matter what weight distribution the patient has. The 
couch can maneuver laterally, longitudinally, vertically, as well as with rotation, pitch 
and roll. The black board on the figure below is the couch top. For most treatments, it is 
through this board that some radiation is required to pass. 
 
Figure 7: The Varian® IGRT Couch Top®
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         The Eclipse® treatment planning system allows the board certified medical physicist 
to incorporate the IGRT Couch Top® in treatment plans if desired. The CT images for the 
four patients did not include the couch when they were treated in the past. In order to 
apply the couch into the planning process, plans were first copied, where the couch 
structure could be inserted. The only way to represent the Varian® IGRT Couch Top® on 
CT images is to assign appropriate values of Hounsfield units to the couch structure, on 
every slice, at precisely the location of the structure. In this manner, the planning system 
would be able to recognize the couch possesses a density, from which to estimate 
attenuation. Since the Varian® IGRT Couch Top® has two parts, the external carbon 
fiber shell and the internal foam filler material, the outer surface was given 700 HU and 
for the internal foam -960 HU. These values were verified by the board certified medical 
physicist during the machine and planning system commissioning process, prior to this 
research. Implementation of the couch in the planning system is shown in figure below. 
  
Figure 8: The IGRT couch model in Eclipse (the couch in pink color after being inserted 
in the patient CT image)
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         Once the IGRT couch inserted in the CT images of couch excluded plans, the dose 
distributions were then recalculated. Dose statistics were then reviewed along with the 
distribution of dose in all planes for analysis.         
3.3 Dose Distribution Analysis 
          Quantitative evaluation of the DVH for each patient was performed. The DVH 
provides numerical information of how much dose is absorbed by each percentage of 
volume for all anatomical structures and targets.14 On the DVH curve, the vertical axis 
represents the volume percentage and the horizontal axis is the relative percentage dose 
(Figure 9). Here, 100% on the x-axis of Figure 9 corresponds to 70 Gy, which is the dose 
prescribed for PTV 70. For example, a percentage volume of 50% on the y-axis 
represents half of the structural volume of the organ or target, and the x-axis value for a 
particular organ receives the stated dose in the plot.
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Figure 9: Dose Volume Histogram (DVH) (each color represents an anatomical structure) 
         
         For the target structures, the mean dose value was evaluated to assess absorbed dose 
estimate shifts induced by the couch.  The dose covering 95% of the volume of the target 
structure (D95%) is evaluated to ensure if the Couch included plan still meets treatment 
planning criteria known as dose-volume constraints (Table 2). Those partial volume dose 
constraints are decided upon by the radiation oncologist. Values for D98%, D50%, and D2% 
are reported to calculate the Homogeneity index (HI). The HI is a ratio used to evaluate 
the dose homogeneity in a target structure, such as PTV 70. As an example, we consider 
the homogeneity index for PTV 70 to be calculated from DVH data using the following
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calculation: HI = (D2%-D98%)/D50%. In this format, D98%, D50%, and D2% represent the dose 
delivered to 98%,50%, and 2% of the volume of the PTV 70, respectively.21 The ideal 
value of HI is zero, revealing a uniform distribution of dose throughout the entire target. 
The HI is used as an indicator, hinting that when values stray far from the intended 0 
heterogeneity mark, that one should closely observe the actual distribution of dose in 
each of the CT views. 
3.4 Beam Attenuation Measurement 
          The aim of this experiment was to identify beam attenuation affects when the 
couch is inserted into patients’ treatment plans. First, in order to verify prior research 
measurements, the impact of gantry angle on beam attenuation was studied with a field 
size of 10x10cm2. The measurement was performed with a Capintec, Inc. ® (Florham 
Park, NJ) Model PR-06C Farmer-type ionization chamber, placed at a depth of 6 cm in a 
CIRS (Norfolk, VA) Plastic Water® phantom. The measurement setup is illustrated in 
Figure 10. A Capintec, Inc. ® Model 192 electrometer was used to measure the 
accumulated charge produced in the ion chamber when irradiated. The phantom was 
aligned longitudinally on the thinner part of the couch. Following that, the couch was 
raised so as to center of the chamber at the isocenter of the Linac. Attenuation was 
measured at various angles. One measurement was obtained with the beam set at an angle 
projecting downward, thus irradiating the ion chamber without first passing through the 
couch. At the angle opposite the first measurement, another measurement was obtained 
with the beam set an angle projecting upward. For an upward beam, the couch would 
need to be penetrated first before the incident x-rays arrive at the ion chamber. A ratio of 
charge collected between the downward projected beam and the upward projected beam 
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give rise to the attenuation exhibited at that angle (i.e. 15° versus 165°). The Beam-on 
time was fixed for all measurements, roughly corresponding to the time to delivery 100 
cGy at dmax.  
 
Figure 10: Measurement setup for couchtop beam attenuation  
            The equation used to calculate the beam attenuation is 
Ion chamber reading without couch for an angle− Ion chamber reading with couch for the opposite angle
Ion chamber reading without couch for the angle
 
3.5 Theoretical Calculations of Couch Attenuation and HU 
         At 6 Mev, the mass attenuation coefficients are 0.02469 cm-2/g and 0.0277 cm-2/g 
for carbon and water respectively.22 The density of carbon fiber is 1.9 g/cm3 and the water 
density is 1 g/cm3.23 Therefore, the linear attenuation coefficients are 0.0469 cm-1 and 
0.0277 cm-1 for carbon and water respectively. The thickness of carbon fiber is 0.6 cm for 
both layers. The following equation was used to calculate the beam attenuation at normal 
incidence and 120º,
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I = Io e
-μ x 
the beam attenuation (%) = 1- (I / Io) ×100.  
At normal incidence x=0.6 cm and at an angle of incidence of 120º, the effective 
thickness of the couch is 1.2 cm. In addition, an estimate of HU for the carbon shell was 
made by using the above linear attenuation coefficients in the equation which defines 
HU:  
HU = (
μ tissue – μ water
μ water
) . 1000. 
This calculated value is compared with the value used experimentally. 
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4.0. RESULTS 
4.1 Results of Beam Attenuation Measurement  
          The beam attenuation of the IGRT Couch Top® as function of gantry angle is 
presented in table 3. The highest beam attenuation is 4.24% with a gantry angle of 120º, 
and the minimum beam attenuation is 2.25% with the gantry angle 180º. These results are 
close to Vanetti et al measurements with attenuation of 2.3% and 3.1% with gantry 
angles of 180º and 135º, respectively.13 
Gantry Angle Measurement 
(NO Couch) 
(Coulomb) 
Measurement 
(IGRT Couch) 
(Coulomb) 
Beam 
Attenuation 
(%) 
 
0º - 180º 89.0 87.0 2.25 
15º - 165º 88.4 86.3 2.38 
30º - 150º 86.1 83.8 2.67 
45º - 135º 83.2 80.0 3.85 
60º - 120º 70.8 67.8 4.24 
Table 3: Beam attenuation of IGRT Couch Top® at different angle 
4.2 Result of Theoretical Calculations of Couch Attenuation and HU 
          The beam attenuations at 0º - 180º and 60º - 120º are 2.8% and 5.0% which are 
very close to values found by measurement of corresponding angles in Table 3. The HU 
of the external shell carbon fiber is 693.5 and this value is similar to the value used in this 
study of 700.  
4.3 Patient Results 
4.3.1 First patient
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         The DVH analysis of target structures for the first patient are shown in Table 4. On 
average, 0.5% (0.35 Gy) of the dose to the PTV 70, and 0.4% of the dose to both PTV 63 
and PTV 56 (0.28 Gy) (not shown) were lost. 
 
 
 
 
 
 
Table 4: First patient DVH analysis for the targets structures 
       The Homogeneity Index (HI) of PTV 70 for the two plans are shown in Table 5. 
 
 
 
Table 5: Homogeneity Index (HI) of PTV 70 for the first patient 
Organ PTV 70 PTV 63 
Parameter 
Couch 
Included 
Couch 
Excluded 
Diff. 
Couch 
Included 
Couch 
Excluded 
Diff. 
Max dose 
[% of 70 
Gy] 
108.4 108.9 -0.5 106.0 104.9 1.1 
Mean 
dose [% 
of 70 Gy] 
102.9 103.4 -0.5 93.8 94.2 -0.4 
D99% [% 
of 70 Gy] 
98.0 99.0 -1.0 87.0 89.0 -2.0 
D95% [% 
of 70 Gy] 
99.5 101.0 -1.5 88.5 90.5 -2.0 
Plan type D2% D50% D98% HI 
Couch Included 74.55 72.1 69.3 0.0728 
Couch Excluded 74.62 72.45 70 0.0638 
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          The results of the DVH analysis for some organs at risk for the first patient are 
summarized in Table 6. 
Table 6: First patient DVH analysis for some organs at risk
Organ Parameter Couch 
Included 
Couch 
Excluded 
Difference 
Mandible 
 
Max dose [%] 100.0 98.7 1.3 
Mean dose [%] 55.2 55.5 -0.3 
D80 [%] 39.5 37.0 2.5 
D30 [%] 71.5 71.5 0.0 
Oral cavity Max dose [%] 107.0 108.5 -1.5 
Mean dose [%] 60.0 59.5 0.5 
D65 [%] 47.5 45.0 2.5 
D45 [%] 80.5 78.0 2.5 
Spinal cord Max dose [%] 56.3 55.3 1.0 
Mean dose [%] 34.4 35.0 -0.6 
D65 [%] 32.5 30.0 2.5 
D45 [%] 47.0 49.5 -2.5 
Larynx Max dose [%] 86.5 84.3 2.2 
Mean dose [%] 63.5 59.6 3.9 
D 90 [%] 56.0 49.5 6.5 
D 40 [%] 64.5 61.5 3.0 
L Parotid Max dose [%] 80.3 82.6 -2.3 
Mean dose [%] 25.4 26.4 -1.0 
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           For the mandible, the maximum dose which covered less than 1% of the whole 
organ’s volume increased by 1.3% (0.9 Gy). D80 is the dose covered 80% of the 
mandible’s volume and it increased by 2.5% (1.75 Gy). The dose distribution difference 
for the mandible is shown on Figure 11 below.  
 
Figure 11: Does percentage distribution for mandible between 85% and 35% of the 
volume 
 
          The dose which is covered the oral cavity when couch being inserted slightly 
increased in two areas from 71% to 62% and 50% to 10% otherwise both scenarios are 
almost identical.
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Figure 12: Does percentage distribution for oral cavity between 75% and 5% of the 
volume 
 
          The volume of spinal cord which is covered by 50% of the prescribed dose (35 Gy) 
dropped from 37% to 25% for the couch excluded plan as shown in the figure below. 
 
Figure 13: Does percentage distribution for spinal cord between 75% and 5% of the 
volume 
 
          For the larynx, the dose discrepancy is more relevant and reach as high as 4.5 Gy. 
However, the mean dose with 63.5% is still less than the constraint which is less than 
79% of the prescribed dose.
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Figure 14: Does percentage distribution for larynx between 95% and 5% of the volume 
4.3.2 Second Patient          
         The DVH of target structures for the third patient are shown in Table 7. The 
average dose losses by target structures are 0.8% (0.56 Gy), 0.9% (0.63 Gy), and 1.2% 
(0.84 Gy) for PTV 70, PTV 63 and PTV 56 (not shown) respectively.
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Organ PTV 70 PTV 63 
Parameter 
Couch 
Included 
Couch 
Excluded 
Diff. 
Couch 
Included 
Couch 
Excluded 
Diff. 
Max dose 
[%] 
108.9 112.4 -3.5 104.6 104.2 0.4 
Mean 
dose [%] 
102.9 103.7 -0.8 93.2 94.1 -0.9 
D99% [%] 98.0 99.0 -1.0 87.0 88.0 -1.0 
D95 [%] 99.5 101.0 -1.5 89.0 90.5 -1.5 
Table 7: Second patient DVH analysis for the targets structures  
The Homogeneity Index (HI) of PTV 70 for the two plans are shown in Table 8. 
Plan type D2% D50% D98% HI 
Couch Included 74.2 72.24 67.2 0.0969 
Couch Excluded 74.97 72.73 69.3 0.0779 
Table 8: Homogeneity Index (HI) of PTV 70 for the second patient
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          The results of the DVH analysis for some organs at risk which the effects are 
statistically significant and more visible for the third patient are summarized in Table 9.  
Organ Parameter Couch 
Included 
Couch 
Excluded 
Difference 
Mandible 
 
Max dose [%] 96.8 96.5 0.3 
Mean dose [%] 19.1 19.6 -0.5 
D30 [%] 31.0 32.0 -1.0 
Oral cavity Max dose [%] 96.7 99.2 -2.5 
Mean dose [%] 28.5 29.0 -0.5 
D35 [%] 39.0 41.5 -2.5 
Spinal cord Max dose [%] 56.5 57.6 -1.1 
Mean dose [%] 22.5 22.2 0.3 
D30 [%] 44.0 42.0 2.0 
Table 9: Second patient DVH analysis for some organs at risk  
           For the mandible and the oral cavity, the mean doses of the couch excluded plans 
are 0.35Gy lower than the mean dose of the Couch included plans.  
 
Figure 15: Does percentage distribution for mandible between 60% and 5% of the 
volume
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          The dose which is covered from 40% to 20% of spinal cord volume increased as 
couch included and reach its maximum with 1.4 Gy higher than the couch excluded plan. 
 
Figure 16: Does percentage distribution for spinal cord between 40% and 5% of the 
volume
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4.3.3 Third Patient 
         The dose statistics of target structures for the third patient are shown in Table 10. 
On average, 0.9% of the dose to the PTV 70, 1.3% of the dose to PTV 63 and 0.7% of the 
dose to PTV 56 (not shown) were lost.  
Organ PTV 70 PTV 63 
Parameter 
Couch 
Included 
Couch 
Excluded 
Diff. 
Couch 
Included 
Couch 
Excluded 
Diff. 
Max dose 
[%] 
111.9 113.6 -1.7 107.4 111.4 -4.0 
Mean 
dose [%] 
105.6 106.5 -0.9 95.3 96.6 -1.3 
D99% [%] 100.0 101.0 -1.0 87.0 88.0 -1.0 
D95 [%] 102.0 103.0 -1.0 90.0 91.0 -1.0 
Table 10: Third patient DVH analysis for the targets structures  
      The Homogeneity Index (HI) of PTV 70 for the two plans are shown in Table 11. 
Plan type D2% D50% D98% HI 
Couch Included 76.65 74.2 70.7 0.0802 
Couch Excluded 77.35 74.69 71.05 0.0843 
Table 11: Homogeneity Index (HI) of PTV 70 for the third patient
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          The results of the DVH analysis for some organs at risk for the third patient are 
shown in Table 12. 
Organ Parameter Couch 
Included 
Couch 
Excluded 
Difference 
Mandible 
 
Max dose [%] 111.9 109.6 2.3 
Mean dose [%] 55.4 56.1 -0.7 
D80 38.5 41.5 -3.0 
R Parotid Max dose [%] 83.2 86.5 -3.3 
Mean dose [%] 32.9 37.5 -4.6 
D60 26.0 31.0 -5.0 
D30 38.0 45.5 -7.5 
Spinal cord Max dose [%] 60.1 67.1 -7.0 
Mean dose [%] 37.3 40.4 -3.1 
D75 25.0 28.0 -3.0 
D20 51.5 57.5 -6.0 
Larynx Max dose [%] 89.3 90.8 -1.5 
Mean dose [%] 62.6 66.9 -4.3 
D80 55.5 60.5 -5.0 
L Parotid Max dose [%] 98.6 103.8 -5.2 
Mean dose [%] 27.7 30.2 -2.5 
D20 53.0 59.5 -6.5 
R brachial 
plexus 
Max dose [%] 85.1 86.4 -1.3 
Mean dose [%] 56.0 53.5 2.5 
D70 40.0 33.0 7.0 
Oral cavity Max dose [%] 95.6 99.1 -3.5 
Mean dose [%] 44.3 45.6 -1.3 
Table 12: Third patient DVH analysis for some organs at risk
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          For the mandible, the mean dose is dropped by 0.5 Gy and the main difference is 
occurred on the dose covered 80% of the mandible volume which is decreased by 2.1 Gy.  
         The dose difference is more relevant for the right parotid gland and reach as high as 
5.25 Gy which is covered 30% of the volume as shown on the figure below. The mean 
dose dropped by 3.22 Gy. 
 
Figure 17: Does percentage distribution for right parotid gland between 90% and 10% of 
the volume
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        The mean dose dropped by 2.17 Gy for the spinal cord and 4.2 Gy higher for the 
dose covered 20% of the volume. 
 
Figure 18: Does percentage distribution for spinal cord between 75% and 10% of the 
volume 
 
         The dose discrepancy for the larynx is more visible and the mean dose decreased by 
3.01 Gy. The maximum difference occurred for the dose that covered 70% of the volume 
and reach 3.85 Gy. 
 
Figure 19: Does percentage distribution for larynx
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        For the left parotid gland, the mean dose dropped by 1.75 Gy and the significant 
difference is 4.55 Gy for the dose covered 20% of the volume. 
        The mean dose increased by 1.75 Gy and the dose difference between the two 
scenarios are mainly occurred on the dose covered from 40% to 90% of the right brachial 
plexus. 
 
Figure 20: Does percentage distribution for right brachial plexus between 90% and 40% 
of the volume 
 
4.3.4 Fourth Patient 
        The DVH of target structures for the fourth patient are shown in Table 13. The 
average dose losses by target structures are 0.9% (0.63 Gy), 1.1% (0.77 Gy), and 0.6% 
(0.42 Gy) for PTV 70, PTV 63 and PTV 56 (not shown) respectively.
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Organ PTV 70 PTV 63 
Parameter 
Couch 
Included 
Couch 
Excluded 
Diff. 
Couch 
Included 
Couch 
Excluded 
Diff. 
Max dose 
[%] 
112.2 112.3 -0.1 104.8 107.2 -2.4 
Mean 
dose [%] 
104.2 105.1 -0.9 94.3 95.4 -1.1 
D99% [%] 98.0 99.0 -1.0 87.0 88.0 -1.0 
D95 [%] 100.0 100.5 -0.5 88.5 90.0 -1.5 
Table 13: Fourth patient DVH analysis for the targets structures  
The Homogeneity Index (HI) of PTV 70 for the two plans are shown in Table 14.  
Plan type D2% D50% D98% HI 
Couch Included 76.3 73.15 68.6 0.1053 
Couch Excluded 76.65 73.64 68.6 0.1093 
Table 14: Homogeneity Index (HI) of PTV 70 for the fourth patient
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          The results of the DVH analysis for some organs at risk for the fourth patient are 
shown in Table 15. 
Organ Parameter Couch 
Included 
Couch 
Excluded 
Difference 
R Parotid Max dose [%] 109.0 109.8 -0.8 
Mean dose [%] 60.9 61.7 -0.8 
Spinal cord Max dose [%] 63.2 68.3 -5.1 
Mean dose [%] 42.6 45.4 -2.8 
D65 48.0 52.5 -4.5 
D30 55.0 59.0 -4.0 
Larynx Max dose [%] 90.9 93.3 -2.4 
Mean dose [%] 66.8 69.2 -2.4 
D90 55.5 59.0 -3.5 
L Parotid Max dose [%] 93.3 91.3 -2.0 
Mean dose [%] 28.9 30.9 -2.0 
D30 35.5 40.0 -4.5 
R brachial 
plexus 
Max dose [%] 82.4 82.7 -0.3 
Mean dose [%] 67.2 67.7 -0.5 
L brachial 
plexus 
Max dose [%] 83.0 84.2 -1.2 
Mean dose [%] 55.2 55.4 -0.3 
D45 75.0 72.0 -3.0 
Table 15: Fourth patient DVH analysis for some organs at risk 
         The dose covered until 70% of the right parotid gland volume is almost identical, 
however the mean dose dropped by 0.56 Gy.
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          For the spinal cord, the mean dose decreased by 1.96 Gy and the discrepancies are 
more visible for the doses covered from 70% to 10% as shown on the figure below. 
 
Figure 21: Does percentage distribution for spinal cord between 70% and 10% of the 
volume 
 
           For the larynx, the mean dose dropped by 1.68 Gy and the biggest difference 
between the two scenarios occurred for the dose covered 90% of the volume. 
 
Figure 22: Does percentage distribution for larynx between 95% and 15% of the volume
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         The dose discrepancy for the left parotid gland between the two planes is visible for 
the doses covered between 70% and 5% of the volume otherwise both planes are 
superimposed. The mean dose decreased by 1.4 Gy.   
 
Figure 23: Does percentage distribution for left parotid gland between 75% and 5% of the 
volume 
 
          For the right brachial plexus, the mean dose dropped by 0.35 Gy. The dose 
differences between the two planes only exist between the doses covered from 85% to 
70% of the volume.
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Figure 24: Does percentage distribution for right brachial plexus between 90% and 65% 
of the volume 
 
           For the left brachial plexus, the mean dose dropped by 0.21 Gy. The couch 
included plane has higher doses from 90% to 60% of the structure volume, however, the 
doses covered from 50% to 30% become higher for the couch excluded plane as shown in 
the figure below. 
 
Figure 25: Does percentage distribution for left brachial plexus between 90% and 20% of 
the volume
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4.4 Summary of Dose Differences between Two Plans for All Patients. 
 
Table 16: Mean dose change in the target structures for the all patients [% of 70 Gy] 
 
Normal 
structures 
 
Patient 1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Spinal cord 
 
-0.6 0.3 -3.1 -2.8 
Mandible 
 
-0.3 -0.5 -0.7 0.1 
L Parotid  
 
-1.0 -0.0 -2.5 -2.0 
R Parotid  
 
-0.5 -0.1 -4.6 -0.5 
Table 17: Mean dose changes for some normal structures [% of 70 Gy]
Target 
Structures 
Patient 1 
 
Patient 2 
 
Patient 3 
 
Patient 4 
 
Average 
change 
 
SD 
 
PTV 70 
 
-0.5 -0.9 -0.9 -0.9 -0.8 0.2 
PTV 63 
 
-0.4 -0.9 -1.3 -1.1 -0.9 0.4 
PTV 56 
 
-0.4 -1.2 -0.7 -0.6 -0.7 0.3 
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5.0 DISCUSSION 
           Overall, the evaluation of the patient DVH data demonstrated a difference between 
dose modeling with the couch present as compared to when the couch was excluded. 
When the IGRT Couch Top® was included in the treatment planning system, there were 
losses of dose and coverage to target structures and dose differences to organs at risk. 
Findings indicate that when treatment planning considers the presence of the couch, 
modeling results reveal volumetric dose differences. In general, the goal of treatment 
planning is to be as accurate as possible, so that when unavoidable dose variations occur 
in actual treatment, they aren’t added to planning errors. 
5.1 Target Structures 
          As mentioned previously in section 2.2.2, the prescription required irradiation of 
three targets: PTV 70, PTV 63, and PTV 56. The mean dose losses to the three target 
structures in all patients, on average, are 0.8%, 0.9%, and 0.7% for PTV 70, PTV 63, and 
PTV 56 respectively. The highest dose reduction of 1.3% for PTV 63 was seen in the 
third patient. However, both plans met the treatment criteria which were summarized in 
Table 1. The dose homogeneity for the PTV 70 was evaluated by calculating the 
homogeneity index (HI). The zero value indicates highly homogeneity in the dose 
distribution. The HI for the Couch excluded plan is 0.08 ± 0.02 and for the Couch 
included plan is 0.09±0.02. For two of the patients the HI was between 0.01 and 0.02 
worse with the couch-included plan.  For the other two patients, there was less difference.
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5.2 Normal Structures 
          For organs-at–risk, there was no consistent overall pattern to conclude any got less 
dose or more dose as a result of considering the couch in the treatment planning process. 
However, the TPS was able to achieve the dose constrains for the organs at risk for both 
plans as it was summarized in Table 2.  
5.2.1 Spinal Cord 
          Maximum doses dropped for three patients and the highest reduction of 7% was 
seen for the third patient. For the first patient, the maximum dose increased 
insignificantly with only 1%. The tolerance of the spinal cord to the radiation therapy is 
that the maximum dose should be less than 50 Gy to avoid the risk of the 
myelopathy.24This limit is not exceeded by any of the cases. 
5.2.2 Mandible 
         The dose differences for the mandible between two scenarios are evaluated for the 
first, second, and third patients, as dose differences were more easily observable from 
DVH plots. The maximum dose increases after the couch tops are included in TPS for 
those patients. The maximum difference of 2.3% is seen in the third patient. However, the 
mean dose decreases for the Couch included plans. 
5.2.3 Larynx 
         The maximum and mean dose increase for the first patient as the couch inserted in 
TPS. However, for the third and fourth patients, these doses are dropped. The highest 
dose reduction was found to be 4.3% is seen in the third patient.
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5.2.4 Right and Left Parotid Gland 
          In the couch included planes, the maximum and mean doses are dropped and the 
highest difference of 5.2% is seen in the third patient. However, the maximum dose of the 
left parotid gland is out of the norm and increases as the couch top considered on the 
plane.
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6.0 CONCLUSION 
           In this study, the effects of the Varian IGRT Couch Top® on the dose distribution 
of the head and neck cancers treatment was determined for a linear accelerator operating 
at 6 MV. Four head and neck cancer patient plans were randomly selected for the study. 
Plans were conducted both with and without couch insertion, where the change in dose 
distribution and volumetric dose statistics in a Varian Model Eclipse® treatment planning 
system would give rise to the consequence of the couch being modeled in the beam. 
Comparisons were made using the planning system’s Dose Volume Histogram (DVH).  
Regarding dose to PTV, both plans achieved the physicians’ dose criteria for all four 
patients.  However, there was a trend with the couch-included plans that the dose barely 
achieved the clinical criteria.  For example, the criteria for PTV 70 was D99 = 97%. The 
four couch excluded plans achieved 99%, 99%, 101%, and 99%, and the four couch 
included plans achieved 98%, 98%, 100%, and 98%. For organs-at–risk, there was no 
consistent overall pattern to conclude any got less dose or more dose as a result of 
considering the couch in the treatment planning process. The results of this work indicate 
that while the treatment couch may make achieving the physician’s criteria more 
difficult, the treatment planning software was able to develop an acceptable plan in all 
cases.
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